JACC: Cardiooncology

Papers
(The TQCC of JACC: Cardiooncology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Editorial Board140
Full Issue PDF133
Full Issue PDF117
Full Issue PDF110
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque108
Priorities in Cardio-Oncology95
Cardiovascular Safety in Oncology Clinical Trials90
Hormonal Therapy and Cardiovascular Health77
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients69
Full Issue PDF63
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy60
Atrial Fibrillation in Patients With Cancer58
Epigenomics of Cardio-Oncology57
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy56
Balancing Promise and Evidence56
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part55
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes53
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies52
Full Issue PDF52
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD50
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy49
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors48
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients46
Cardiac Risk Stratification Before Lung Cancer Radiation46
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA43
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis43
Frailty42
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms39
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis38
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma38
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)37
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy37
PROPORTIONATE AND ABSOLUTE PULMONARY EMBOLISM MORTALITY IN ONCOLOGY IN THE UNITED STATES FROM 1999-201935
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients34
Editorial Board/Officers Page34
Cancer Immunotherapy Beyond Checkpoint Blockade33
Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer33
Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer32
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD31
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance29
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors29
Full Issue PDF28
Editorial Board28
Permissive Cardiotoxicity28
TRASTUZUMAB CARDIOTOXICITY IN EARLY STAGE HER2 POSITIVE BREAST CANCER PATIENTS IN MEXICO27
SUCCESSFUL DIAGNOSIS AND SURGICAL RESECTION OF A PULMONIC SARCOMATOID CARCINOMA LACKING PET AVIDITY OR MALIGNANT APPEARING CMR TISSUE CHARACTERISTICS27
Quality-of-Care Measures for Cardio-Oncology27
Developing a Model for Cross-Institutional Educational Collaborations25
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity25
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity24
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation22
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research21
Leveling Up21
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction21
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy21
Vascular Complications of Atrial Fibrillation in Patients With Cancer20
Endothelin-120
JACC: CardioOncology20
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia19
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer19
Low QRS Voltages in Cardiac Amyloidosis19
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy19
A CHALLENGING CASE OF A LARGE RIGHT HEART MASS COMPLICATED BY COMPLETE HEART BLOCK18
The United Kingdom’s First Cardio-Oncology Service18
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge18
Assessing Silent Cardiotoxicity in Long-Term Lymphoma Survivors Treated With Radiotherapy17
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction17
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy17
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients17
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer17
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.16
Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer16
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity16
Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent16
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity16
CHA2DS2-VASc Score in Cardio-Oncology16
Fluoropyrimidine Therapy in Gastrointestinal Cancer15
How to Perform Hematopoietic Stem Cell Transplantation15
To Adjudicate or Not Adjudicate15
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors15
Full Issue PDF15
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction15
Hearts on the Minds of Oncologists15
Full Issue PDF14
Cancer Therapy–Related Cardiac Dysfunction14
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity14
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy14
ABSTRACT WITHDRAWN14
SEX DIFFERENCES IN ANTHRACYCLINE-TREATED CANCER SURVIVORS ASSESSED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING14
Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors14
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?14
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors14
Author Index14
Cardiovascular Considerations After Cancer Therapy14
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer13
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors13
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY13
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness13
JACC: CardioOncology13
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?13
PALLIATIVE RESECTION OF A CARDIAC SARCOMA12
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT12
(Less) Time and Energy11
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction11
Clinical Practice Guidelines in Cardio-Oncology11
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer11
Cardiovascular Care After Cancer11
Guiding Treatment With Recovered CTRCD11
Navigating the Uncharted11
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer11
The Cause of Death in Patients With Cancer10
Considerations of Competing Risks Analysis in Cardio-Oncology Studies10
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors10
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB10
Reply10
Addressing the Overlooked10
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity10
Full Issue PDF10
ASYMPTOMATIC CARDIAC METASTASIS OF NEUROENDOCRINE TUMOR DIAGNOSED BY PET CT SCAN10
Reply10
Reply10
Preventing Cancer Therapy–Related Cardiotoxicity10
Editorial Board/Officers Page10
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy9
TYROSINE KINASE INHIBITOR ASSOCIATED POLYMORPHIC VENTRICULAR TACHYCARDIA9
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients9
The ESC Cardio-Oncology Guidelines9
Amyloid Cardiomyopathy9
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation9
Reply9
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors9
Reply9
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy9
When Clot Is Tumor8
Overcoming LGBTQI+ Disparities in Cardio-Oncology8
Full Issue PDF8
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population8
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category8
Learning From Trials8
Assessing STEMI Outcomes in Patients With Cancer8
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology8
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients8
FIRST DOSE ORTHOSTATIC HYPOTENSION FOLLOWING DOCETAXEL AND GEMCITABINE INFUSION7
Reply7
Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer7
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice7
Cancer Diagnosis, Physical Activity, and Heart Disease Risk7
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity7
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy7
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors7
Reply7
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients7
Editorial Board7
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy7
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma7
0.069278955459595